Skip to main content
. 2022 Jun 28;40(25):2946–2956. doi: 10.1200/JCO.21.02772

FIG 1.

FIG 1.

CONSORT diagram. AE, adverse event; BC, breast cancer; ddAC, dose-dense doxorubicin and cyclophosphamide; H, trastuzumab; ITT, intention-to-treat; IV, intravenous; P, pertuzumab; Pac, paclitaxel.